Clinical Trial Update: Valsartan to Prevent Left Ventricle Remodeling in Pacemaker Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating valsartan to prevent left ventricle remodeling in patients with a first-time dual-chamber pacemaker implantation; the study was termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Left Ventricular Remodeling

Drugs mentioned

• VALSARTAN (Valsartan)

Snippet

Sponsor: Medical University of Silesia | Conditions: First Time Dual Chamber Pacemaker Implantation | Phase 4 | Status: TERMINATED